ELAN vs. JAZZ, APLS, CYTK, IONS, VKTX, CERE, ITCI, BPMC, ASND, and MDGL
Should you be buying Elanco Animal Health stock or one of its competitors? The main competitors of Elanco Animal Health include Jazz Pharmaceuticals (JAZZ), Apellis Pharmaceuticals (APLS), Cytokinetics (CYTK), Ionis Pharmaceuticals (IONS), Viking Therapeutics (VKTX), Cerevel Therapeutics (CERE), Intra-Cellular Therapies (ITCI), Blueprint Medicines (BPMC), Ascendis Pharma A/S (ASND), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "pharmaceutical preparations" industry.
Elanco Animal Health (NYSE:ELAN) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.
Elanco Animal Health currently has a consensus price target of $16.71, suggesting a potential upside of 24.27%. Jazz Pharmaceuticals has a consensus price target of $195.08, suggesting a potential upside of 77.88%. Given Jazz Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Jazz Pharmaceuticals is more favorable than Elanco Animal Health.
In the previous week, Jazz Pharmaceuticals had 7 more articles in the media than Elanco Animal Health. MarketBeat recorded 10 mentions for Jazz Pharmaceuticals and 3 mentions for Elanco Animal Health. Jazz Pharmaceuticals' average media sentiment score of 0.66 beat Elanco Animal Health's score of 0.36 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media.
Jazz Pharmaceuticals received 963 more outperform votes than Elanco Animal Health when rated by MarketBeat users. Likewise, 80.49% of users gave Jazz Pharmaceuticals an outperform vote while only 54.17% of users gave Elanco Animal Health an outperform vote.
Jazz Pharmaceuticals has a net margin of 10.82% compared to Elanco Animal Health's net margin of -27.87%. Jazz Pharmaceuticals' return on equity of 31.27% beat Elanco Animal Health's return on equity.
Jazz Pharmaceuticals has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Elanco Animal Health has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500.
97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 0.6% of Elanco Animal Health shares are owned by insiders. Comparatively, 4.4% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Jazz Pharmaceuticals beats Elanco Animal Health on 15 of the 18 factors compared between the two stocks.
Get Elanco Animal Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELAN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Elanco Animal Health Competitors List
Related Companies and Tools
